Journal CHEST®

Pretreatment With Mono or Dual Pulmonary Hypertension-Targeted Medical Therapy in Patients Undergoing Balloon Pulmonary Angioplasty
By D.P. Staal, and colleagues
The 2022 European Society of Cardiology/European Respiratory Society guidelines conditionally recommend medical pretreatment before balloon pulmonary angioplasty (BPA) in patients with inoperable chronic thromboembolic pulmonary hypertension and pulmonary vascular resistance (PVR) >4WU, based largely on riociguat monotherapy data. This retrospective multicenter study included 169 patients receiving monotherapy (55%) or dual pulmonary hypertension (PH)-targeted therapy (45%; an endothelin receptor antagonist plus riociguat or a phosphodiesterase-5 inhibitor).
Dual therapy was associated with fewer thoracic complications per BPA session (8.4% vs 19.6%; P <.001), while monotherapy had higher adjusted odds of complications (OR, 3.33; 95% CI, 1.43-7.69). At first BPA, the dual therapy group had lower PVR (3.7 vs 5.8 WU) and higher cardiac index (3.1 vs 2.6 L/min/m2). From pretreatment baseline to six months after BPA, the dual therapy group had greater median improvements in 6-minute walk distance (+86 vs +30 m), cardiac index (+1.2 vs +0.4 L/min/m2), and PVR (-6.1 vs -4.0 WU). These observational findings support further investigation of dual pretreatment before BPA.
Commentary by Marwa Oudah, MD, FCCP, Member of the CHEST Physician Editorial Board
CHEST® Critical Care

A Novel Noninvasive Tool to Assess Recruitability During Assisted Ventilation
By Luca Bastia, MD, and colleagues
In pressure support, positive end-expiratory pressure (PEEP) titration still lacks a simple bedside marker of recruitability. Bastia and colleagues test one: the sigh-to-tidal compliance ratio (S/T), respiratory-system compliance during a mandatory 30 cm H2O sigh divided by compliance of an assisted tidal breath.
Among 100 analyzable patients, an S/T greater than 1 (36%) identified those in whom a 3 cm H2O PEEP increase raised tidal compliance (48 to 53 mL/cm H2O) and the Pao2/Fio2 ratio (269 to 308), with a small fall in driving pressure and no hemodynamic cost. An S/T of 1 or less was associated with the opposite pattern. The ratio also tracked volume recruited beyond the prediction from baseline compliance alone.
The method needs no esophageal balloon, impedance tomography, or imaging, but the sigh itself is a research maneuver, not routine practice. The cohort was only mildly hypoxemic, the PEEP step was modest, and no clinical outcomes were assessed. An S/T greater than 1 is a plausible signal to test a small PEEP increase; an S/T of 1 or less is not a mandate to lower PEEP. Validation in ARDS is required before clinical use.
Commentary by Jojo Alunilkummannil, MBBS, Member of the CHEST Physician Editorial Board
CHEST® Pulmonary

An Evidence-Based Exposure Questionnaire for Interstitial Lung Disease
By Kerri A. Johannson, MD, MPH, and colleagues
For patients with interstitial lung disease (ILD), identifying relevant exposures can inform diagnosis and opportunities for risk reduction. Johannson and colleagues combine published evidence with international expert consensus to develop EXPO-ILD, comprising a nine-question screen and a comprehensive questionnaire. These tools could make exposure assessment more systematic and prompt focused discussion of exposures at home and work. Clinicians must then clarify their timing, intensity, and plausibility before recommending mitigation. A reported exposure does not establish causality, and questionnaire responses must be interpreted alongside other clinical findings.
Predominant North American and European representation reinforces the need for regional adaptation and patient input. Prospective validation must establish whether these tools improve exposure identification and clinical decisions. They support structured conversations with patients; effects on disease progression and quality of life remain untested. Individualized advice on reducing relevant exposures may help patients take an active role in their care and regain a sense of control.
Commentary by Priya Balakrishnan, MD, MS, FCCP, Member of the CHEST Physician Editorial Board